Nephrosant

About Nephrosant

Nephrosant, Inc. operates as a biotechnology company focused on the diagnostics market for kidney disease. The company was established in 2017 as a spin-out from the University of California, San Francisco (UCSF) by Dr. Minnie M. Sarwal and Joshua Young Yang. Dr. Sarwal, who serves as the CEO, is a distinguished nephrologist and researcher in transplant immunology with extensive experience at UCSF and Stanford University. Her research, particularly in developing noninvasive methods for monitoring organ transplant health, forms the scientific foundation of the company.

Nephrosant is centered on developing noninvasive diagnostic solutions for the early detection and management of kidney disease and transplant rejection. The company's primary clients are physicians and kidney transplant recipients. Its business model involves providing laboratory-developed tests (LDTs) from its CLIA-certified lab. Revenue is generated through reimbursement for these tests, with a significant milestone being the local coverage determination from the Centers for Medicare & Medicaid Services (CMS) for its flagship product.

The company's lead product is QSant™, a urine-based test designed to detect the risk of kidney transplant rejection. This test offers a significant advantage over the standard of care, which often involves invasive and costly biopsies. QSant™ allows for at-home sample collection; patients provide a single urine sample that is shipped to Nephrosant's lab for analysis. The test analyzes a panel of six biomarkers, including cell-free DNA, using a proprietary algorithm to generate a personalized "Q-Score™" that quantifies the risk of rejection. This score enables clinicians to make timely adjustments to immunosuppressive therapy, potentially improving long-term graft survival. In March 2022, Nephrosant launched the AQUA study, a two-year clinical trial involving 2,000 kidney transplant recipients to further validate the clinical benefits of QSant™.

Financially, Nephrosant secured $16 million in a Series A funding round in March 2021, led by DaVita Venture Group with participation from DigitalDx Ventures and others. This funding was aimed at supporting the commercial launch of QSant™ and further research and development.